The VA Prescribes Opioids. It Won’t Recommend Cannabis. A Bipartisan Bill Is Trying to Change That.

H.R. 2072 would end the VA’s blanket prohibition on recommending medical cannabis — but only in states where it’s already legal, and only if the our legislative tracker can clear a committee where its predecessors have repeatedly stalled.

A veteran in Colorado with chronic pain from blast injuries can legally purchase cannabis at a licensed dispensary. What they cannot do is discuss it with their VA doctor — not without that doctor risking federal employment, and not without the veteran risking their benefits. The opioids their VA doctor can recommend are a different matter. Those are fine.

H.R. 2072 — the Veterans Equal Access to Cannabis Therapy Act of 2026 — would change the cannabis side of that equation. Introduced in February and referred to the House Veterans’ Affairs Committee with bipartisan co-sponsors, it is a deliberately narrow bill doing one targeted thing: allowing VA physicians to recommend medical cannabis to veterans in states where it is legal, without facing federal discipline, and without threatening the veteran’s access to federal benefits.

It does not federally legalize cannabis. It does not override state law. It does not turn the VA into a cannabis provider. It asks only that the federal government stop punishing its own doctors and their patients for complying with laws that 38 states have already passed.

What This Bill Actually Does

The VA operates under federal law, which classifies cannabis as a Schedule I controlled substance — meaning, legally, no accepted medical use whatsoever. In practice, this produces a set of specific prohibitions that H.R. 2072 would modify:

– VA physicians currently cannot recommend or discuss medical cannabis with patients in any clinical context, in any state – Veterans discovered to be using cannabis — even legally, even in states where it is fully licensed — can face loss of VA housing assistance, benefit determinations, and in some cases employment referrals – VA employees, including healthcare providers, are subject to federal employment rules that prohibit cannabis use and advocacy

H.R. 2072 carves out one exception: in states with existing legal medical cannabis programs, VA healthcare providers would be permitted to recommend cannabis as a treatment option, document it in patient records, and have those discussions protected from federal employment discipline. The veteran would then obtain cannabis through normal state-licensed channels — the VA would not dispense it, purchase it, or administer it.

What this bill does not change: it has no effect on veterans in non-legal states. It does not create a federal cannabis program. It does not address recreational use. The recommendation authority ends at the state line.

Who It Affects

More than 9 million veterans are enrolled in the VA healthcare system. The VA’s own data consistently documents disproportionately high rates of chronic pain, PTSD, and traumatic brain injury — particularly among post-9/11 veterans who served in combat theaters where blast injuries and repeated concussive exposure were routine.

These are the veterans this bill is aimed at. Not recreational users seeking a federal imprimatur — veterans who have often already exhausted opioid-based treatment, who are aware of cannabis’s documented effects on pain and anxiety, who live in states that have already deemed it legal medical care, and who are currently navigating it without medical guidance because their government won’t allow their doctor to acknowledge it exists.

The scale of this population is not theoretical. A 2021 VA survey found that approximately 1 in 5 veterans reported cannabis use in the prior year. A significant portion live in legal states. Under current policy, their VA physicians cannot advise them on dosing, interactions with other medications, or efficacy for specific conditions — because any discussion could constitute “recommending” a controlled substance.

Research context matters here. A study published in March 2026 found that plant-derived cannabis extracts significantly outperformed FDA-approved synthetic THC (dronabinol) in elderly patients managing chronic pain — with lower dropout rates and better patient-reported outcomes. That research won’t change VA policy by itself. But it illustrates the gap between what federal scheduling permits in clinical settings and what the actual evidence is producing.

The Direction

This is an expansion bill, and an incremental one. It does not seek to settle the federal scheduling debate — it seeks to stop the VA from using that debate as justification for denying veterans access to information and medical guidance their states have already made available.

The directional trend is consistent. Veterans’ cannabis access legislation has been introduced in multiple successive Congresses. Support from veterans’ organizations has broadened. The specific politics of this issue — “why won’t you let a veteran’s doctor help them?” — are difficult to defend in public, which is why opposition tends to be structural rather than vocal.

The bipartisan framing matters. Rep. Brian Mast (R-FL), the bill’s primary sponsor, is a double-amputee combat veteran who lost both legs serving in Afghanistan. His advocacy for veterans’ cannabis access is substantive, not symbolic. His Republican backing provides cover for colleagues who might otherwise face intra-party pushback, and signals that this issue’s trajectory cuts across the normal partisan lines on cannabis policy.

What Happens Next

H.R. 2072 was referred to the House Veterans’ Affairs Committee in February 2026 with bipartisan co-sponsors. No markup or hearing is currently scheduled.

The pattern here is well-established: strong co-sponsor lists, vocal veterans’ group support, and committee stall. The bill’s closest predecessors — including the VA Medicinal Cannabis Research Act and earlier versions of the Veterans Equal Access Act — followed this arc. They generated support, cleared co-sponsor thresholds, and did not advance to a floor vote.

Two things could change that trajectory in this Congress:

The DEA rescheduling process. If the DEA moves cannabis from Schedule I to Schedule III — a final rule still pending after the public comment period closed in March — the legal underpinning of the VA’s blanket prohibition weakens significantly. Schedule III status would acknowledge that cannabis has accepted medical uses; the VA’s position that it cannot discuss a substance with “no accepted medical use” becomes operationally incoherent.

Veterans’ organization pressure. The American Legion, IAVA, and DAV have all pushed for VA cannabis policy reform at various stages. Sustained advocacy from these organizations — which carry significant weight with committee members regardless of party — remains the most reliable mechanism for forcing a markup.

What could kill it: floor time competition, leadership opposition from those who see incremental cannabis wins as a path toward full legalization, or inaction by committee chairs who would prefer the issue stay in the gray zone.

Who’s Behind This

Rep. Brian Mast (R-FL) is the bill’s lead sponsor and its most credible advocate. A Republican veteran who has been public about the limitations of the VA’s opioid-dependent pain management approach, Mast’s support is not ideologically convenient — it’s experiential. His record on veterans’ healthcare legislation is consistent, and his willingness to break with Republican leadership on cannabis-adjacent issues has been documented across multiple Congresses.

Bipartisan co-sponsors have attached to the bill, reinforcing that veterans’ cannabis access occupies unusual political terrain. The voting math on this issue tends to favor the bill at the co-sponsor stage; the problem is the gap between co-sponsor signatures and committee time.

Veterans’ advocacy organizations — including IAVA, the American Legion, and DAV — have each pushed variations of this policy ask in recent years. Their continued engagement makes silence on the bill politically expensive for committee chairs, even if it doesn’t guarantee a hearing.

Committee resistance (structural, not stated): The House Veterans’ Affairs Committee has authority over this bill. The implicit opposition comes from leadership wary of providing incremental cannabis normalization without a broader policy framework. That opposition rarely states itself plainly — it manifests as scheduling inaction rather than recorded votes.

The Bottom Line

Veterans in legal states are already using cannabis. Their VA doctors are currently forbidden from acknowledging it clinically. H.R. 2072 would fix that gap — narrowly, carefully, without expanding federal legalization by a single millimeter. The bill has co-sponsors, veterans’ group support, and a sponsor with the credibility to hold the argument together. What it doesn’t have is a hearing date. That’s the only thing standing between this bill and a committee vote.